South Korean (KOSPI) Clinical Research and Equipment Industry Analysis

Industry Valuation and Performance

Has the South Korean Clinical Research and Equipment Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 17 Jun 2026	₩75.5t	₩5.7t	₩1.5t	16.3x	51.2x	13.2x
Fri, 15 May 2026	₩85.0t	₩5.7t	₩1.5t	38.3x	55x	14.9x
Sun, 12 Apr 2026	₩90.6t	₩5.4t	₩1.4t	43x	64.3x	16.6x
Tue, 10 Mar 2026	₩91.1t	₩5.4t	₩1.5t	16.5x	60.5x	16.8x
Thu, 05 Feb 2026	₩99.3t	₩5.4t	₩1.5t	17.2x	65.6x	18.3x
Sat, 03 Jan 2026	₩94.3t	₩6.4t	₩1.5t	16.6x	63.1x	14.8x
Mon, 01 Dec 2025	₩93.2t	₩6.4t	₩1.5t	17.3x	62.4x	14.7x
Wed, 29 Oct 2025	₩102.0t	₩5.8t	₩1.2t	16.1x	86x	17.4x
Fri, 26 Sep 2025	₩87.5t	₩5.8t	₩1.2t	14.9x	73.8x	15x
Sun, 24 Aug 2025	₩88.1t	₩5.8t	₩1.2t	25.1x	72.5x	15.1x
Tue, 22 Jul 2025	₩88.7t	₩5.7t	₩1.2t	16.6x	72.4x	15.6x
Thu, 19 Jun 2025	₩82.0t	₩5.6t	₩1.2t	15.6x	66.5x	14.6x
Sat, 17 May 2025	₩82.0t	₩5.2t	₩1.0t	17.5x	80x	15.7x
Mon, 14 Apr 2025	₩84.5t	₩5.2t	₩1.0t	18x	82.1x	16.2x
Wed, 12 Mar 2025	₩84.2t	₩5.2t	₩996.4b	12.3x	84.5x	16.2x
Fri, 07 Feb 2025	₩86.9t	₩5.0t	₩965.6b	12.8x	90x	17.4x
Sun, 05 Jan 2025	₩76.0t	₩5.0t	₩965.6b	13.3x	78.7x	15.2x
Tue, 03 Dec 2024	₩76.6t	₩5.0t	₩945.3b	13.2x	81x	15.2x
Thu, 31 Oct 2024	₩82.5t	₩4.8t	₩885.3b	13.2x	93.2x	17x
Sat, 28 Sep 2024	₩77.5t	₩4.8t	₩885.3b	14.6x	87.5x	16x
Mon, 26 Aug 2024	₩75.1t	₩4.8t	₩868.1b	18.8x	86.5x	15.5x
Wed, 24 Jul 2024	₩67.6t	₩4.5t	₩731.7b	19.3x	92.3x	14.9x
Fri, 21 Jun 2024	₩59.3t	₩4.6t	₩691.8b	18.5x	85.7x	12.9x
Sun, 19 May 2024	₩61.8t	₩4.4t	₩664.2b	19.9x	93.1x	14x
Tue, 16 Apr 2024	₩62.8t	₩4.7t	₩654.7b	18.8x	95.9x	13.5x
Thu, 14 Mar 2024	₩65.5t	₩4.6t	₩636.6b	29.6x	102.9x	14.1x
Sat, 10 Feb 2024	₩63.4t	₩4.5t	₩714.4b	33.8x	88.8x	14x
Mon, 08 Jan 2024	₩60.1t	₩4.5t	₩721.5b	32.6x	83.4x	13.2x
Wed, 06 Dec 2023	₩56.6t	₩4.5t	₩721.6b	30.8x	78.5x	12.5x
Fri, 03 Nov 2023	₩55.9t	₩4.4t	₩660.9b	23.6x	84.6x	12.7x
Sun, 01 Oct 2023	₩54.3t	₩4.4t	₩660.9b	30.3x	82.1x	12.3x
Tue, 29 Aug 2023	₩59.2t	₩4.4t	₩693.2b	29x	85.4x	13.4x
Thu, 27 Jul 2023	₩56.7t	₩4.2t	₩673.4b	26.1x	84.2x	13.5x
Sat, 24 Jun 2023	₩58.2t	₩4.2t	₩666.5b	29.9x	87.3x	13.7x

Current Industry PE

Investors are pessimistic on the South Korean Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 51.0x which is lower than its 3-year average PE of 80.7x.

The 3-year average PS ratio of 15.1x is higher than the industry's current PS ratio of 13.2x.

Past Earnings Growth

The earnings for companies in the Life Sciences Tools and Services industry have grown 30% per year over the last three years.
Revenues for these companies have grown 10% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does South Korean Clinical Research and Equipment compare with similar industries?


KR Market	7.52%
Healthcare	3.13%
Life Sciences	2.28%
Clinical Research and Equipment	2.28%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
A207940 Samsung BiologicsLtd	₩1.37m	5.7% +₩3.4t	-11.1%	PE36.2x
A141080 LigaChem Biosciences	₩139.70k	9.1% +₩431.1b	25.6%	PS40.9x
A494120 Curiosis	₩29.95k	12.6% +₩25.5b	n/a	PS32.6x
A038290 Macrogen	₩13.86k	14.6% +₩19.2b	-11.4%	PE39.4x
A002630 ORIENT BIO	₩946.00	10.4% +₩5.3b	-45.2%	n/a

New minor risk - Shareholder dilution

The company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 20% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Revenue is less than US$5m (₩5.0b revenue, or US$3.2m). Market cap is less than US$100m (₩143.0b market cap, or US$91.7m).

South Korean (KOSPI) Clinical Research and Equipment Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

Now 36% overvalued

Investor sentiment improves as stock rises 21%

ORIENT BIO Inc., Annual General Meeting, Jun 29, 2026

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

We're Interested To See How LigaChem Biosciences (KOSDAQ:141080) Uses Its Cash Hoard To Grow

New minor risk - Market cap size

First quarter 2026 earnings released

Invites Biocore Co., Ltd., Annual General Meeting, Mar 30, 2026

Progen Co., Ltd., Annual General Meeting, Mar 31, 2026

HLB bioStep Co.,Ltd., Annual General Meeting, Mar 26, 2026

Peptron, Inc., Annual General Meeting, Mar 26, 2026

New minor risk - Share price stability

FutureChem Co.,Ltd, Annual General Meeting, Mar 26, 2026

MEDIZEN HUMANCARE Inc., Annual General Meeting, Mar 31, 2026